Single photon-emission computed tomography imaging in early Parkinson’s disease

References

• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol.56, 33–39 (1999).
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry51, 745–752 (1988).
   PubMed Web of Science ®Google Scholar
• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol.5, 75–86 (2006).
   PubMed Web of Science ®Google Scholar
• Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can. J. Neurol. Sci.18, 275–278 (1991).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of the clinical diagnosis of Parkinson’s disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55, 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Mark MH, Sage JI, Dickson DW, Schwarz KO, Duvoisin RC. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases. Neurology7, 1323–1327 (1992).
   Google Scholar
• Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson disease. Arch. Neurol.50, 140–148 (1993).
   PubMed Web of Science ®Google Scholar
• Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing28, 99–102 (1999).
   PubMed Web of Science ®Google Scholar
• Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat. Disord.13, 2–7 (2007).
   Google Scholar
• Arvanitakis Z, Wilson RS, Schneider JA et al. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology63, 996–1001 (2004).
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology69, 1542–1550 (2007).
   PubMed Web of Science ®Google Scholar
• Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol.3, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology69, 1701–1711 (2007).
   PubMed Web of Science ®Google Scholar
• Delong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol.64, 20–24 (2007).
   PubMedGoogle Scholar
• Gonera EG, Van’t Hof M, Berger HJ, Van Weel C, Horstink MW. Symptoms and duration of the premotor phase in Parkinson’s disease. Mov. Disord.12, 871–876 (1997).
   PubMed Web of Science ®Google Scholar
• Becker G, Müller A, Braune S et al. Early diagnosis of Parkinson’s disease. J. Neurol.3, 40–48 (2002).
   Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Nonmotor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.3, 235–245 (2006).
   Google Scholar
• Chaudhuri KR, Martinez-Martin P. Quantitation of nonmotor symptoms in Parkinson’s disease. Eur. J. Neurol.15, 2–7 (2008).
   PubMed Web of Science ®Google Scholar
• Marras C, Lang A. Changing concepts in Parkinson disease: moving beyond the Decade of the Brain. Neurology70, 1996–2003 (2008).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, White LR et al. Environmental, life-style and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu–Asia aging study. J. Neurol.250, 30–39 (2003).
   Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging.24, 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Iranzo A. Molinuevo JL, Santamaría J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol.5, 572–577 (2006).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology13, 16–25 (2008).
   Google Scholar
• Groenewegen HJ, Berendse HW. The specificity of the ‘nonspecific’ midline and intralaminar thalamic nuclei. Trends Neurosci.17, 52–57 (1994).
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Frey KA, Marek KL et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp. Neurol.184, 68–79 (2003).
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann. Neurol.53, 110–118 (2003).
   PubMedGoogle Scholar
• Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson’s disease progression: what can we learn from neuroimaging studies. Ann. Neurol.53, 160–166 (2003).
   Google Scholar
• Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease. Mov. Disord.18, 63–70 (2003).
   Google Scholar
• Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson’s disease progression. J. Neurol.251, 9–13 (2004).
   Google Scholar
• Ravina B, Eidelberg D, Ahlskog JE et al. The role of radiotracer imaging in Parkinson disease. Neurology64, 208–215 (2005).
   PubMed Web of Science ®Google Scholar
• Nestler J, Hyman SE, Malenka RC. Catecholamines. In: Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. Nestler EJ, Hyman SE Malenka RC (Eds). McGraw-Hill, NY, USA (2001).
   Google Scholar
• Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson’s disease and control substantia nigra neurons. Ann. Neurol.35, 494–498 (1994).
   PubMedGoogle Scholar
• Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol.388, 211–227 (1997).
   PubMed Web of Science ®Google Scholar
• Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci.16, 436–447 (1996).
   PubMedGoogle Scholar
• Bezard E, Dovero S, Prunier C et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J. Neurosci.21, 6853–6861 (2001).
   PubMed Web of Science ®Google Scholar
• Innis RB. Single photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson’s disease. Eur. J. Nucl. Med.21, 1–5 (1994).
   PubMedGoogle Scholar
• Innis RB, Seibyl JP, Scanley BE et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. Proc. Natl Acad. Sci. USA90, 11965–11969 (1993).
   PubMedGoogle Scholar
• Seibyl JP. Single-photon emission computed tomography of the dopamine transporter in parkinsonism. J. Neuroimaging9, 223–228 (1999).
   PubMedGoogle Scholar
• Carroll FI, Scheffel U, Dannals RF et al. Development of imaging agents for the dopamine transporter. Med. Res. Rev.15, 419–444 (1995).
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Marek KL, Quinlan D et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann. Neurol.38, 589–598 (1995).
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Marek K, Sheff K et al. Test/retest reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters in Parkinson’s patients. J. Nucl. Med.38, 1453–1459 (1997).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gandelman MS, DeErausquin GA et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J. Nucl. Med.37, 1129–1133 (1996).
   PubMed Web of Science ®Google Scholar
• Booij J, Tissingh G, Winogrodzka A et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur. J. Nucl. Med.24, 68–71 (1997).
   PubMedGoogle Scholar
• Goodman MM, Kung M-P, Kabalka GW et al. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents. J. Med. Chem.37, 1535–1542 (1994).
   PubMedGoogle Scholar
• Mozley PD, Stubbs JB, Kim H-J et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J. Nucl. Med.37, 151–159 (1996).
   PubMedGoogle Scholar
• Tatsch K, Schwarz J, Mozley PD et al. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single photon emission tomography. Eur. J. Nucl. Med.24, 415–421 (1997).
   PubMedGoogle Scholar
• Fischman AJ, Bonab AA, Babich JW et al. Rapid detection of Parkinson’s disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse29, 128–141 (1998).
   PubMedGoogle Scholar
• Madras BK, Meltzer PC, Liang AY et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse29, 93–104 (1998).
   PubMedGoogle Scholar
• Seibyl JP, Marek K, Sheff K et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J. Nucl. Med.39, 1500–1508 (1998).
   PubMedGoogle Scholar
• Neumeyer JL, Wang SY, Milius RA et al. [123I]-2 β-carbomethoxy-3 β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J. Med. Chem.34, 3144–3146 (1991).
   PubMed Web of Science ®Google Scholar
• Mozley PD, Schneider JS, Acton PD et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J. Nucl. Med.41, 584–589 (2000).
   PubMed Web of Science ®Google Scholar
• Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson’s disease with 99mTc-TRODAT-1 imaging. J. Nucl. Med.42, 1303–1308 (2001).
   PubMed Web of Science ®Google Scholar
• Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson’s disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J. Nucl. Med.42, 408–413 (2001).
   PubMed Web of Science ®Google Scholar
• Weng YH, Yen TC, Chen MC et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson’s disease from healthy subjects. J. Nucl. Med.45, 393–401 (2004).
   PubMed Web of Science ®Google Scholar
• Booij J, Speelman JD, Horstink HW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur. J. Nucl. Med.28, 266–272 (2001).
   PubMedGoogle Scholar
• Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm.38, 277–301 (1976).
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson’s disease. Adv. Neurol.45, 19–34 (1987).
   PubMedGoogle Scholar
• Tissingh G, Bergmans P, Booij J et al. Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT. J. Neurol.245, 14–20 (1998).
   PubMed Web of Science ®Google Scholar
• Tissingh G, Booij J, Bergmans P et al. Iodine-123-N-Vfluoropropyl-2β-carbomethoxy-3β-[4-iodophenyl]tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J. Nucl. Med.39, 1143–1114 (1998).
   PubMed Web of Science ®Google Scholar
• Marek K, Innis R, van Dyck C et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology57, 2089–2094 (2001).
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: SN regional selectivity. Brain114, 2283–2301 (1991).
   PubMed Web of Science ®Google Scholar
• Morrish PK, Rakshi JS, Bailey DL, Sawle GV Brooks DJ. Measuring the rate of progression and estimating the premotoral period of Parkinson’s disease with [18F]DOPA PET. J. Neurol. Neurosurg. Psychiatry64, 314–319 (1998).
   PubMed Web of Science ®Google Scholar
• Berendse HW, Booij J, Francot CM et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann. Neurol.50, 34–41 (2001).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54, 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Morrish PK. Real-PET and CONSORT. Ann. Neurol.54, 692–693 (2003).
   PubMedGoogle Scholar
• Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology64, A274 (2005).
   Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287, 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J. Neural Transm.108, 1011–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl. Med. Commun.27, 933–937 (2006).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group PRECEPTS Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology69, 1480–1490 (2007).
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU. Imaging evidence supports a link between essential tremor and Parkinson’s disease. Nucl. Med. Comm. (2008) (In Press).
   PubMedGoogle Scholar
• Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]β-CIT and SPECT in essential tremor and Parkinson’s disease. J. Neural Transm.105, 1213–1228 (1998).
   PubMed Web of Science ®Google Scholar
• Benamer HTS, Patterson J, Grosset DG. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]FP-CIT SPECT imaging: the [123I]FP-CIT SPECT study group. Mov. Disord.15, 503–510 (2000).
   PubMed Web of Science ®Google Scholar
• Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol.7, 27 (2007).
   PubMed Web of Science ®Google Scholar
• Vlaar AM, de Nijs T, Kessel AG et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur. Neurol.59, 258–266 (2008).
   PubMed Web of Science ®Google Scholar
• Isaias IU, Canesi M, Benti R et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl. Med. Commun.29, 349–353 (2008).
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang YP, Liu XD et al.99mTc-TRODAT-1 SPECT study in early Parkinson’s disease and essential tremor. Acta Neurol. Scand.112, 380–385 (2005).
   PubMedGoogle Scholar
• Antonini A. Berto P, Lopatriello S et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson’s disease in Italy. Mov. Disord. (2008) (Epub ahead of print).
   Google Scholar
• Antonini A, Benti R, De Notaris R et al. [123I]-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol. Sci.24, 149–150 (2003).
   PubMed Web of Science ®Google Scholar
• Scherfler C, Seppi K, Donnemiller E et al. Voxel-wise analysis of [123I]-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson’s disease. Brain128, 1605–1612 (2005).
   PubMedGoogle Scholar
• Zijlmans JCM, Daniel SE, Hughes AJ, Révész T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov. Disord.19, 630–640 (2004).
   PubMed Web of Science ®Google Scholar
• Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord.22, 1229–1238 (2007).
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Linszen DH, Booij J et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr. Res.47, 59–67 (2001).
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I] FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov. Disord.21, 510–514 (2006).
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Ottaviani S, Isaias IU et al. [123I]FP-CIT SPET imaging in drug induced parkinsonism. Mov. Disord.23(13), 1825–1829 (2008).
   PubMedGoogle Scholar
• Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G. Measuring the progression of idiopathic Parkinson’s disease with [123I]-CIT SPECT. J. Neural Transm.107, 543–552 (2000).
   PubMedGoogle Scholar
• Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl. Med. Commun.22, 721–725 (2001).
   PubMedGoogle Scholar
• Colloby SJ, Williams ED, Burn DJ et al. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging32, 1176–1185 (2005).
   PubMedGoogle Scholar
• Kung HF, Guo YZ, Billings J et al. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int. J. Rad. Appl. Instrum.15, 195–201 (1988).
   Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med.36, 1182–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Murphy RA, Kung HF, Kung MP, Billings J. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J. Med. Chem.33, 171–178 (1990).
   PubMed Web of Science ®Google Scholar
• Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J. Nucl. Med.31, 648–654 (1990).
   PubMedGoogle Scholar
• Schwarz J, Tatsch K, Arnold G et al.123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology42, 556–561 (1992).
   PubMedGoogle Scholar
• Hierholzer J, Cordes M, Schelosky L et al. The differential diagnosis of Parkinson diseases-123I-IBZM-SPECT vs the apomorphine test. Rofo159, 86–90 (1993).
   PubMedGoogle Scholar
• Antonini A, Vontobel P, Psylla M et al. Complementary PET studies of the striatal dopaminergic system in Parkinson’s disease. Arch. Neurol.52, 1183–1192 (1995).
   PubMedGoogle Scholar
• Pizzolato G, Cagnin A, Rossato A et al. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson’s disease. A [123I]IBZM SPET study. Adv. Neurol.69, 467–473 (1996).
   PubMedGoogle Scholar
• Hierholzer J, Cordes M, Venz S et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J. Nucl. Med.39, 954–960 (1998).
   PubMedGoogle Scholar
• Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med.26, 171–182 (1999).
   PubMedGoogle Scholar
• Prunier C, Tranquart F, Cottier JP et al. Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl. Med. Commun.22, 1207–1214 (2001).
   PubMedGoogle Scholar
• Knudsen GM, Karlsborg M, Thomsen G et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging31, 1631–1638 (2004).
   PubMed Web of Science ®Google Scholar
• Buck A, Westera G, Sutter M et al. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J. Nucl. Med.36, 1196–1200 (1995).
   PubMedGoogle Scholar
• Aarsland D, Karlsen K. Neuropsychiatric aspects of Parkinson’s disease. Curr. Psychiatry Rep.1, 61–68 (1999).
   PubMedGoogle Scholar
• Antonini A. Unraveling depression in Parkinson’s disease. Eur. J. Neurol.15(9), 885–886 (2008).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem.40, 288–295 (1994).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry5, 32–38 (2000).
   PubMed Web of Science ®Google Scholar
• Suehiro M, Scheffel UA, Ravert HT et al. Highly potent indanamine serotonin uptake blockers as radiotracers for imaging serotonin uptake sites. Nucl. Med. Biol.21, 1083–1091 (1994).
   PubMedGoogle Scholar
• Szabo Z, Kao PF, Scheffel U et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)MCN5652. Synapse20, 37–43 (1995).
   PubMedGoogle Scholar
• Szabo Z, Mohamadiyeh M, Scheffel U et al. Impulse-response function and kinetic-model of C-11-labeled (+)MCN5652. J. Nucl. Med.37, 125 (1996).
   Google Scholar
• Szabo Z, Scheffel U, Mathews WB et al. Kinetic analysis of [11C]McN5652. A serotonin transporter radioligand. J. Cereb. Blood Flow Metab.19, 967–981 (1999).
   PubMedGoogle Scholar
• Parsey RV, Kegeles LS, Hwang DR et al.In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J. Nucl. Med.41, 1465–1477 (2000).
   PubMedGoogle Scholar
• Maryanoff EM, Vaught JL, Shank RP et al. Pyrroloisoquinoleines antidepressants. A focus on serotonin. J. Med. Chem.33, 2793–2797 (1990).
   PubMedGoogle Scholar
• Laruelle M, Baldwin RM, Malison RT et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse13, 295–309 (1993).
   PubMed Web of Science ®Google Scholar
• Kuikka JT, Bergstrom KA, Ahonen A et al. Comparison of iodine-123 labelled 2 β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur. J. Nucl. Med.22, 356–360 (1995).
   PubMedGoogle Scholar
• Fujita M, Takatoku K, Matoba Y et al. Differential kinetics of [123I]β-CIT binding to dopamine and serotonin transporters. Eur. J. Nucl. Med.23, 431–436 (1996).
   PubMedGoogle Scholar
• Tiihonen J, Kuikka JT, Bergstrom KA et al. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behavior. Eur. J. Nucl. Med.24, 1253–1260 (1997).
   PubMedGoogle Scholar
• Malison RT, Price LH, Berman R et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry44, 1090–1098 (1998).
   PubMed Web of Science ®Google Scholar
• Meltzer CC, Smith G, DeKosky ST et al. Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology18, 407–430 (1998).
   PubMed Web of Science ®Google Scholar
• Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol. Psychiatry44, 534–549 (1998).
   PubMed Web of Science ®Google Scholar
• Willeit M, Praschak-Rieder N, Neumeister A et al. [123I]β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol. Psychiatry47, 482–489 (2000).
   PubMed Web of Science ®Google Scholar
• Caretti V, Stoffers D, Winogrodzka A et al. Loss of thalamic serotonin transporters in early drug-naive Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study. J. Neural Transm.115, 721–729 (2008).
   PubMed Web of Science ®Google Scholar
• Bergstrom KA, Halldin C, Hall H et al.In vitro and in vivo characterization of nor-β-CIT: a potential radioligand for visualization of the serotonin transporter in the brain. Eur. J. Nucl. Med.24, 596–601 (1997).
   PubMedGoogle Scholar
• Blough BE, Abraham P, Mills AC et al. 3β-(4-ethyl-3-iodophenyl)nortropane-2 β-carboxylic acid methyl ester as a high-affinity selective ligand for the serotonin transporter. J. Med. Chem.40, 3861–3864 (1997).
   PubMedGoogle Scholar
• Hiltunen J, Akerman KK, Kuikka JT et al. Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur. J. Nucl. Med.25, 19–23 (1998).
   PubMedGoogle Scholar
• Oya S, Kung M-P, Acton PD et al. A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I] IDAM, 5-iodo-2-((2-((dimethyl- amino)methyl)phenyl)thio)benzyl alcohol. J. Med. Chem.42, 333–335 (1999).
   PubMed Web of Science ®Google Scholar
• Zhuang ZP, Choi SR, Hou C et al. A novel serotonin transporter ligand: (5-iodo-2-(2-di-methylaminomethylphenoxy)-benzyl alcohol (ODAM). Nucl. Med. Biol.27, 169–175 (2000).
   PubMed Web of Science ®Google Scholar
• Acton PD, Kung MP, Mu M et al. Single-photon emission tomography imaging of serotonin transporters in the non-human primate brain with the selective radioligand [123I]IDAM. Eur. J. Nucl. Med.26, 854–861 (1999).
   PubMedGoogle Scholar
• Kung MP, Hou C, Oya S et al. Characterization of [123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur. J. Nucl. Med.26, 844–853 (1999).
   PubMedGoogle Scholar
• Sacher J, Asenbaum S, Klein N. Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. Int. J. Neuropsychopharmacol.10, 1–8 (2006).
   Google Scholar
• Erlandsson K, Sivananthan T, Lui D et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur. J. Nucl. Med. Mol. Imaging32, 1329–1336 (2005).
   PubMed Web of Science ®Google Scholar
• Klein N, Sacher J, Geiss-Granadia T et al.In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl.)188, 263–272 (2006).
   PubMed Web of Science ®Google Scholar
• Klein N, Sacher J, Geiss-Granadia T et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl.)191, 333–339 (2007).
   PubMed Web of Science ®Google Scholar
• Tamagnan GD, Brennerb E, Alagillea D et al. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg. Med. Chem. Lett.15, 533–537 (2007).
   Google Scholar
• Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol.6, 926–932 (2007).
   PubMed Web of Science ®Google Scholar
• Feigin A, Antonini A, Fukuda M et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov. Disord.17, 1265–1270 (2002).
   PubMedGoogle Scholar
• Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson’s disease. Eur. J. Nucl. Med. Mol. Imaging30, 16–24 (2003).
   PubMedGoogle Scholar
• Van Laere K, De Ceuninck L, Dom R et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1. Eur. J. Nucl. Med. Mol. Imaging31, 1119–1127 (2004).
   PubMedGoogle Scholar
• Cilia R, Siri C, Marotta G et al. Brain networks underlining verbal fluency decline during STN-DBS in Parkinson’s disease: an ECD-SPECT study. Parkinsonism Relat. Disord.13, 290–294 (2007).
   PubMedGoogle Scholar
• Antonini A, De Notaris R, Benti R et al. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson’s disease. Neurol. Sci.22, 45–46 (2001).
   PubMedGoogle Scholar
• Antonini A, Benti R, Righini A, Pezzoli G. Sensitivity and specificity of ECD/SPECT and high field (1,5T) MRI in the differential diagnosis between MSA and Parkinson’s disease. Neurology52, S351 (1999).
   PubMedGoogle Scholar
• Derejko M, Slawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson’s disease as an indicator of cognitive impairment. Nucl. Med. Commun.27, 945–951 (2006).
   PubMedGoogle Scholar
• Chang CC, Liu JS, Chang YY, Chang WN, Chen SS, Lee CH. (99m)Tc-ethyl cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson’s disease patients: a correlation with neuropsychological tests. Eur. J. Neurol.15, 61–65 (2008).
   PubMedGoogle Scholar
• Kageyama H, Kikuchi S, Tashiro K. Analysis of Parkinson’s disease and related syndromes using 123I-IMP-SPECT with the ARG method. Nippon Rinsho55, 238–242 (2007).
   Google Scholar
• Hayashi H, Odano I, Nishihara M, Higuchi S, Sakai K, Ishikawa A. Clinical evaluation of Parkinson’s disease using 123I-IMP SPECT. Kaku Igaku26, 1405–1415 (1989).
   PubMedGoogle Scholar
• Kamei H, Nakajima T, Fukuhara N. Statistic rCBF study of extrapyramidal disorders. No To Shinkei54, 667–672 (2002).
   PubMedGoogle Scholar
• Matsui H, Udaka F, Miyoshi T et al. Brain perfusion differences between Parkinson’s disease and multiple system atrophy with predominant parkinsonian features. Parkinsonism Relat. Disord.11, 227–232 (2005).
   PubMedGoogle Scholar
• Matsui H, Nishinaka K, Oda M et al. Heterogeneous factors in dementia with Parkinson’s disease: IMP-SPECT study. Parkinsonism Relat. Disord.13, 174–181 (2006).
   PubMedGoogle Scholar
• Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson’s disease. Mov. Disord.18, 39–42 (2003).
   Google Scholar
• Pizzolato G, Chierichetti F, Rossato A et al. Dopamine receptor SPET imaging in Parkinson’s disease: a [123I]-IBZM and [99mTc]-HM-PAO study. Eur. Neurol.33, 143–148 (1993).
   PubMedGoogle Scholar
• Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H. Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders. Nuklearmedizin33, 184–188 (1994).
   PubMedGoogle Scholar
• Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson’s disease before and after levodopa: correlation with dopaminergic responsiveness. J. Neurol. Neurosurg. Psychiatry57, 180–185 (1994).
   PubMedGoogle Scholar
• Liu RS, Lin KN, Wang SJ et al. Cognition and 99Tcm-HMPAO SPECT in Parkinson’s disease. Nucl. Med. Commun.13, 744–748 (1992).
   PubMedGoogle Scholar
• Wang SJ, Liu RS, Liu HC et al. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson’s disease: correlation with dementia and lateralization. Eur. J. Nucl. Med.20, 339–344 (1993).
   PubMedGoogle Scholar
• Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: comparison with Parkinson’s disease and normal controls. Mov. Disord.10, 179–187 (1995).
   PubMed Web of Science ®Google Scholar
• Varma AR, Talbot PR, Snowden JS, Lloyd JJ, Testa HJ, Neary D. A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J. Neurol.244, 349–359 (1997).
   PubMedGoogle Scholar
• Donnemiller E, Heilmann J, Wenning GK et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I – CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur. J. Nucl. Med.24, 320–325 (1997).
   PubMedGoogle Scholar
• Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J. Neurol. Neurosurg. Psychiatry64, 306–313 (1998).
   PubMed Web of Science ®Google Scholar
• Defebvre LJ, Leduc V, Duhamel A et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J. Nucl. Med.40, 956–962 (1999).
   PubMedGoogle Scholar
• Cummings JL. Depression and Parkinson’s disease:a review. Am. J. Psychiatry149, 443–454 (1992).
   PubMed Web of Science ®Google Scholar
• Koller WC. Sensory symptoms in Parkinson’s disease. Neurology34, 957–959 (1984).
   PubMed Web of Science ®Google Scholar
• Santamaria J, Tolosa E, Valles A. Parkinson’s disease with depression: a possible subgroup ofidiopathic parkinsonism. Neurology36, 1130–1133 (1986).
   PubMed Web of Science ®Google Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neuologic signs, disease stage, or disease duration. Neurology38, 1237–1244 (1988).
   PubMed Web of Science ®Google Scholar
• Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S The olfactory and cognitive deficits of Parkinson’s disease: evidence for independence. Ann. Neurol.25, 166–171 (1989).
   PubMedGoogle Scholar
• Ward CD, Duvoisin RC, Ince SE et al. Parkinson’s disease in twins. Adv. Neurol.40, 341–344 (1984).
   PubMedGoogle Scholar
• Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology53, 1020–1025 (1999).
   PubMed Web of Science ®Google Scholar
• Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov. Disord.18, 890–897 (2003).
   PubMed Web of Science ®Google Scholar
• Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann. Nucl. Med.18, 453–461(2004).
   PubMed Web of Science ®Google Scholar
• Iwasa K, Nakajima K, Yoshikawa H, Tada A, Taki J, Takamori M. Decreased myocardial 123I-MIBG uptake in Parkinson’s disease. Acta Neurol. Scand.97, 303–306 (1998).
   PubMedGoogle Scholar
• Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci.155, 60–67 (1998).
   PubMed Web of Science ®Google Scholar
• Taki J, Nakajima K, Hwang EH et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med.27, 566–573 (2000).
   PubMedGoogle Scholar
• Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology53, 1020–1025 (1999).
   PubMed Web of Science ®Google Scholar
• Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry67, 189–194 (1999).
   PubMed Web of Science ®Google Scholar
• Druschky A, Hilz MJ, Platsch G et al. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci.175, 3–12 (2000).
   PubMed Web of Science ®Google Scholar
• Takatsu H, Nishida H, Matsuo H et al. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med.41, 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry76, 249–251 (2005).
   PubMedGoogle Scholar
• Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov. Disord.15, 1004–1008 (2007).
   Google Scholar
• Schneider SA, Edwards MJ, Mir P et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov. Disord.22, 2210–2215 (2007).
   PubMed Web of Science ®Google Scholar
• Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov. Disord.13, 438–445 (1998).
   PubMedGoogle Scholar
• Vaamonde J, Ibáñez R, García AM, Poblete V. Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients. Neurologia19, 292–300 (2004).
   PubMedGoogle Scholar
• Plotkin M, Amthauer H, Klaffke S et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm.112, 677–692 (2005).
   PubMed Web of Science ®Google Scholar
• Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson’s disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur. J. Nucl. Med. Mol. Imaging34, 502–507 (2007).
   PubMedGoogle Scholar